Scarica l'app Stockscreener
1.14
3.67%
0.05
Dopo l'orario di chiusura:
1.14
Precedente Chiudi:
$1.09
Aprire:
$1.07
Volume 24 ore:
323.85K
Relative Volume:
0.10
Capitalizzazione di mercato:
$143.89M
Reddito:
$3.25M
Utile/perdita netta:
$-116.80M
Rapporto P/E:
-0.3738
EPS:
-3.05
Flusso di cassa netto:
$-98.17M
1 W Prestazione:
-9.60%
1M Prestazione:
-4.24%
6M Prestazione:
-50.22%
1 anno Prestazione:
-86.95%
Intervallo 1D:
$1.07
$1.14
Intervallo di 1 settimana:
$1.07
$1.28
Portata 52W:
$0.7893
$10.05
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Nome
Rapt Therapeutics Inc
Settore
Industria
Telefono
(650) 489-9000
Indirizzo
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Confronta RAPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
1.14 | 143.89M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Downgrade | Stifel | Buy → Hold |
| 2024-11-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-02-22 | Downgrade | UBS | Buy → Neutral |
| 2024-02-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Iniziato | Evercore ISI | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-09-14 | Iniziato | Berenberg | Buy |
| 2023-08-09 | Iniziato | Stifel | Buy |
| 2023-06-15 | Iniziato | Barclays | Overweight |
| 2023-01-04 | Iniziato | Guggenheim | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | CapitalOne | Overweight |
| 2022-05-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Iniziato | JP Morgan | Overweight |
| 2021-08-12 | Iniziato | SVB Leerink | Outperform |
| 2021-06-21 | Iniziato | Piper Sandler | Overweight |
| 2020-06-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Iniziato | ROTH Capital | Buy |
| 2019-11-25 | Iniziato | BMO Capital Markets | Outperform |
| 2019-11-25 | Iniziato | UBS | Buy |
| 2019-11-25 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Rapt Therapeutics Inc Borsa (RAPT) Ultime notizie
RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World
Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
SG Americas Securities LLC Purchases 42,636 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
FY2024 Earnings Forecast for RAPT Issued By Leerink Partnrs - Defense World
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy - Yahoo Finance
RAPT Therapeutics Inc (NASDAQ: RAPT) Up 31.9% From 52-Week Low; YTD Falls -26.58% – Here’s What To Do Now - Marketing Sentinel
A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - US Post News
A stock that deserves closer examination: Solidion Technology Inc (STI) - US Post News
Analytical Lens: Exploring RAPT Therapeutics Inc (RAPT)’s Financial Story Through Ratios - The Dwinnex
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com
SEC Form 424B3 filed by RAPT Therapeutics Inc. - Quantisnow
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stake Boosted by Barclays PLC - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Jane Street Group LLC - Defense World
RAPT Therapeutics Plans Phase 2b Trials for RPT904 - TipRanks
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Purchased by Barclays PLC - Defense World
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
RAPT Therapeutics appoints new board chair By Investing.com - Investing.com Nigeria
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - Insights
RAPT Therapeutics appoints new board chair - Investing.com
RAPT Therapeutics, Inc. Announces Board Changes - Marketscreener.com
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
RAPT Therapeutics Names Former BOTOX Leader Lori Lyons-Williams as Board Chair - StockTitan
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $9.56 Average Target Price from Brokerages - MarketBeat
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of “Hold” from Analysts - Defense World
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - News & Insights
Short Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Grows By 25.5% - MarketBeat
Notable analyst calls this week: FREYR Battery, Apple and ServiceNow among top picks - Seeking Alpha
Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright - Yahoo Finance
RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to Buy Rating - Defense World
RAPT rockets 180% on licensing deal, $150M private placement (update) - MSN
RAPT Therapeutics Shares Surge After HC Wainwright Upgrade - Marketscreener.com
HC Wainwright & Co. Upgrades RAPT Therapeutics (RAPT) - MSN
RAPT upgraded at H.C. Wainwright on China licensing deal - MSN
RAPT stock upgraded at H.C. Wainwright (RAPT:NASDAQ) - Seeking Alpha
RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to "Buy" Rating - MarketBeat
RAPT Therapeutics Announces License Agreement and Private Placement - Defense World
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement - Yahoo Finance
RAPT Therapeutics soars as it looks to raise $150M in private placement - MSN
RAPT Therapeutics sees 113% spike on allergy med licensing deal & private placement - Mugglehead
RAPT Therapeutics, Inc. announced that it expects to receive $149.976555 million in funding from a group of investors - Marketscreener.com
RAPT Therapeutics stock rises following licensing deal with Jemincare By Investing.com - Investing.com Nigeria
RAPT Therapeutics stock rises following licensing deal with Jemincare - Investing.com
Peninsula drugmaker lands $150 million, food allergy drug to fill pipeline holeSan Francisco Business Times - The Business Journals
Why RAPT Therapeutics Stock Gained Over 100% On Monday? - Yahoo Finance
US Stocks Mixed, Dow Tumbles 150 Points - Benzinga
Stock market today: iLearningEngines plunges by 60.44% while Reliance Global Group surged by 231.67% in early trading session - Business Upturn
RAPT Therapeutics secures rights to new allergy antibody - Investing.com
Rapt Therapeutics Inc Azioni (RAPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.95%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):